1. Home
  2. BOLD vs XOS Comparison

BOLD vs XOS Comparison

Compare BOLD & XOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • XOS
  • Stock Information
  • Founded
  • BOLD 2018
  • XOS 2016
  • Country
  • BOLD United States
  • XOS United States
  • Employees
  • BOLD N/A
  • XOS N/A
  • Industry
  • BOLD
  • XOS Construction/Ag Equipment/Trucks
  • Sector
  • BOLD
  • XOS Consumer Discretionary
  • Exchange
  • BOLD Nasdaq
  • XOS Nasdaq
  • Market Cap
  • BOLD 30.3M
  • XOS 25.6M
  • IPO Year
  • BOLD 2024
  • XOS N/A
  • Fundamental
  • Price
  • BOLD $1.10
  • XOS $3.30
  • Analyst Decision
  • BOLD Buy
  • XOS Buy
  • Analyst Count
  • BOLD 3
  • XOS 5
  • Target Price
  • BOLD $4.00
  • XOS $8.80
  • AVG Volume (30 Days)
  • BOLD 362.2K
  • XOS 20.2K
  • Earning Date
  • BOLD 08-11-2025
  • XOS 08-12-2025
  • Dividend Yield
  • BOLD N/A
  • XOS N/A
  • EPS Growth
  • BOLD N/A
  • XOS N/A
  • EPS
  • BOLD N/A
  • XOS N/A
  • Revenue
  • BOLD N/A
  • XOS $48,678,000.00
  • Revenue This Year
  • BOLD N/A
  • XOS $1.45
  • Revenue Next Year
  • BOLD N/A
  • XOS $27.16
  • P/E Ratio
  • BOLD N/A
  • XOS N/A
  • Revenue Growth
  • BOLD N/A
  • XOS N/A
  • 52 Week Low
  • BOLD $1.00
  • XOS $2.73
  • 52 Week High
  • BOLD $4.72
  • XOS $9.15
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • XOS 56.65
  • Support Level
  • BOLD N/A
  • XOS $3.00
  • Resistance Level
  • BOLD N/A
  • XOS $3.15
  • Average True Range (ATR)
  • BOLD 0.00
  • XOS 0.11
  • MACD
  • BOLD 0.00
  • XOS 0.04
  • Stochastic Oscillator
  • BOLD 0.00
  • XOS 84.41

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About XOS Xos Inc.

Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Classes 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.

Share on Social Networks: